Total Payments
$29,235
2022 Payments
$1,375
Companies
11
Transactions
51
Medicare Patients
598
Medicare Billing
$69,957
Payment Breakdown by Category
Consulting$15,350 (52.5%)
Travel$6,256 (21.4%)
Research$5,006 (17.1%)
Other$2,000 (6.8%)
Food & Beverage$598.73 (2.0%)
Education$23.95 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $15,350 | 6 | 52.5% |
| Travel and Lodging | $6,256 | 21 | 21.4% |
| Unspecified | $5,006 | 2 | 17.1% |
| Honoraria | $2,000 | 1 | 6.8% |
| Food and Beverage | $598.73 | 19 | 2.0% |
| Education | $23.95 | 2 | 0.1% |
Payments by Type
General
$24,228
49 transactions
Research
$5,006
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Pharmacyclics LLC, an AbbVie Company | $10,746 | 22 | $0 (2022) |
| Adaptive Biotechnologies Corporation | $4,832 | 2 | $0 (2020) |
| Celgene Corporation | $4,717 | 1 | $0 (2018) |
| AbbVie, Inc. | $4,173 | 7 | $0 (2019) |
| Akcea Therapeutics, Inc. | $3,123 | 7 | $0 (2019) |
| GlaxoSmithKline, LLC. | $1,495 | 5 | $0 (2019) |
| Amgen Inc. | $60.88 | 3 | $0 (2021) |
| Janssen Biotech, Inc. | $40.23 | 1 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $24.00 | 1 | $0 (2019) |
| Karyopharm Therapeutics Inc. | $12.45 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $1,375 | 1 | Pharmacyclics LLC, an AbbVie Company ($1,375) |
| 2021 | $2,006 | 4 | Pharmacyclics LLC, An AbbVie Company ($1,925) |
| 2020 | $4,844 | 3 | Adaptive Biotechnologies Corporation ($4,832) |
| 2019 | $7,684 | 15 | AbbVie, Inc. ($3,300) |
| 2018 | $8,847 | 16 | Celgene Corporation ($4,717) |
| 2017 | $4,478 | 12 | Pharmacyclics LLC, An AbbVie Company ($4,189) |
All Payment Transactions
51 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/17/2022 | Pharmacyclics LLC, an AbbVie Company | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $1,375.00 | General |
| Category: ONCOLOGY | ||||||
| 09/21/2021 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $40.23 | General |
| Category: Oncology | ||||||
| 06/16/2021 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $1,925.00 | General |
| Category: ONCOLOGY | ||||||
| 05/17/2021 | Amgen Inc. | Kyprolis (Drug) | Food and Beverage | In-kind items and services | $29.22 | General |
| Category: Oncology | ||||||
| 02/22/2021 | Epizyme, Inc., | TAZVERIK (Drug) | Education | In-kind items and services | $11.50 | General |
| Category: ONCOLOGY | ||||||
| 11/17/2020 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Education | In-kind items and services | $12.45 | General |
| Category: Oncology | ||||||
| 01/02/2020 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Consulting Fee | Cash or cash equivalent | $4,500.00 | General |
| Category: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | ||||||
| 01/02/2020 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Travel and Lodging | Cash or cash equivalent | $332.04 | General |
| Category: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | ||||||
| 12/08/2019 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $49.99 | General |
| 12/08/2019 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $19.60 | General |
| 07/18/2019 | Akcea Therapeutics, Inc. | TEGSEDI (Drug) | Honoraria | Cash or cash equivalent | $2,000.00 | General |
| Category: NEUROLOGY | ||||||
| 07/18/2019 | Akcea Therapeutics, Inc. | TEGSEDI (Drug) | Travel and Lodging | Cash or cash equivalent | $48.74 | General |
| Category: NEUROLOGY | ||||||
| 07/10/2019 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $918.44 | General |
| 07/10/2019 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $217.60 | General |
| 06/15/2019 | Akcea Therapeutics, Inc. | TEGSEDI (Drug) | Travel and Lodging | In-kind items and services | $493.60 | General |
| Category: NEUROLOGY | ||||||
| 06/15/2019 | Akcea Therapeutics, Inc. | TEGSEDI (Drug) | Travel and Lodging | In-kind items and services | $315.56 | General |
| Category: NEUROLOGY | ||||||
| 06/15/2019 | Akcea Therapeutics, Inc. | TEGSEDI (Drug) | Food and Beverage | In-kind items and services | $23.77 | General |
| Category: NEUROLOGY | ||||||
| 06/15/2019 | Akcea Therapeutics, Inc. | TEGSEDI (Drug) | Food and Beverage | In-kind items and services | $13.26 | General |
| Category: NEUROLOGY | ||||||
| 06/14/2019 | Akcea Therapeutics, Inc. | TEGSEDI (Drug) | Travel and Lodging | In-kind items and services | $227.75 | General |
| Category: NEUROLOGY | ||||||
| 04/06/2019 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $24.00 | General |
| 03/08/2019 | AbbVie, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| 03/05/2019 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $15.83 | General |
| 02/28/2019 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $15.83 | General |
| 11/12/2018 | AbbVie, Inc. | Venclexta (Drug) | Travel and Lodging | In-kind items and services | $442.40 | General |
| Category: Virology | ||||||
| 11/10/2018 | AbbVie, Inc. | Venclexta (Drug) | Food and Beverage | In-kind items and services | $49.73 | General |
| Category: Virology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RV-FOL-GELARC-0683C - A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Ly | Celgene Corporation | $4,717 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 46 | 71 | $20,055 | $6,138 |
| 2022 | 3 | 55 | 63 | $18,335 | $6,286 |
| 2021 | 4 | 250 | 452 | $78,202 | $28,829 |
| 2020 | 5 | 247 | 418 | $120,795 | $28,704 |
Total Patients
598
Total Services
1,004
Medicare Billing
$69,957
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 19 | 37 | $8,047 | $2,505 | 31.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 16 | 23 | $6,750 | $2,355 | 34.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 11 | 11 | $5,258 | $1,277 | 24.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 17 | 17 | $8,479 | $2,964 | 35.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 25 | 29 | $5,389 | $1,799 | 33.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 13 | 17 | $4,467 | $1,523 | 34.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 131 | 268 | $37,677 | $13,658 | 36.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 84 | 144 | $31,401 | $11,953 | 38.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 21 | 22 | $7,862 | $2,800 | 35.6% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 14 | 18 | $1,262 | $418.16 | 33.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 142 | 304 | $82,290 | $19,169 | 23.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 26 | 26 | $15,280 | $3,837 | 25.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 29 | 34 | $13,965 | $3,162 | 22.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 38 | 42 | $7,021 | $1,706 | 24.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 12 | 12 | $2,239 | $830.26 | 37.1% |
About Dr. Edward Libby, MD
Dr. Edward Libby, MD is a Hematology healthcare provider based in San Diego, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1417978651.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Edward Libby, MD has received a total of $29,235 in payments from pharmaceutical and medical device companies, with $1,375 received in 2022. These payments were reported across 51 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($15,350).
As a Medicare-enrolled provider, Libby has provided services to 598 Medicare beneficiaries, totaling 1,004 services with total Medicare billing of $69,957. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Hematology
- Location San Diego, CA
- Active Since 07/22/2006
- Last Updated 11/13/2025
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1417978651
Products in Payments
- Imbruvica (Drug) $7,446
- clonoSEQ (Device) $4,832
- Revlimid (Drug) $4,717
- IMBRUVICA (Drug) $3,300
- TEGSEDI (Drug) $3,123
- Venclexta (Drug) $872.65
- DARZALEX (Biological) $40.23
- Kyprolis (Drug) $29.22
- XPOVIO (Drug) $12.45
- TAZVERIK (Drug) $11.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in San Diego
Bassel El-Rayes, Md, MD
Hematology — Payments: $113,779
Hematology $113,779
Huan-You Wang, Md, Phd, MD, PHD
Hematology — Payments: $29,106
Hematology $29,106
Dr. John Adamson, Md, MD
Hematology — Payments: $15,759
Hematology $15,759
Thomas Sweet, Md, MD
Hematology — Payments: $3,264
Hematology $3,264
Dr. Edward Ball, M.d, M.D
Hematology — Payments: $2,712
Hematology $2,712
Priya Singh, M.d, M.D
Hematology — Payments: $2,006
Hematology $2,006